X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9631) 9631
Publication (349) 349
Newsletter (122) 122
Magazine Article (62) 62
Book Review (42) 42
Newspaper Article (42) 42
Conference Proceeding (29) 29
Dissertation (11) 11
Book Chapter (10) 10
Paper (9) 9
Trade Publication Article (2) 2
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5901) 5901
hydrochlorothiazide (4747) 4747
male (4194) 4194
hypertension - drug therapy (3639) 3639
female (3564) 3564
middle aged (3225) 3225
hydrochlorothiazide - therapeutic use (3173) 3173
adult (2373) 2373
aged (2274) 2274
hypertension (2113) 2113
blood pressure - drug effects (1932) 1932
drug therapy, combination (1766) 1766
diuretics (1528) 1528
antihypertensive agents - therapeutic use (1523) 1523
index medicus (1503) 1503
hydrochlorothiazide - administration & dosage (1463) 1463
pharmacology & pharmacy (1303) 1303
hydrochlorothiazide - adverse effects (1271) 1271
hydrochlorothiazide - pharmacology (1237) 1237
double-blind method (1075) 1075
hypertension - physiopathology (1030) 1030
animals (1016) 1016
drug combinations (885) 885
peripheral vascular disease (855) 855
treatment outcome (747) 747
antihypertensive agents - administration & dosage (723) 723
rats (694) 694
blood pressure (689) 689
diuretics - therapeutic use (680) 680
blood-pressure (661) 661
antihypertensive agents - adverse effects (649) 649
clinical trials as topic (644) 644
time factors (635) 635
medicine, general & internal (583) 583
drug therapy (563) 563
tablets (472) 472
chemistry, analytical (468) 468
valsartan (468) 468
amlodipine (439) 439
dose-response relationship, drug (436) 436
cardiac & cardiovascular systems (435) 435
adolescent (425) 425
hypertension - complications (413) 413
hypertension - blood (412) 412
potassium - blood (409) 409
antihypertensive agents - pharmacology (406) 406
therapy (391) 391
research (388) 388
heart rate - drug effects (386) 386
angiotensin-converting enzyme inhibitors - therapeutic use (371) 371
tetrazoles - therapeutic use (368) 368
risk factors (364) 364
losartan (356) 356
diuretics - pharmacology (332) 332
aged, 80 and over (328) 328
sodium chloride symporter inhibitors - therapeutic use (326) 326
prospective studies (321) 321
double-blind (311) 311
random allocation (301) 301
efficacy (300) 300
combination therapy (295) 295
risk (292) 292
diuretics - administration & dosage (287) 287
analysis (284) 284
diuretics - adverse effects (282) 282
renin - blood (277) 277
drugs (276) 276
dosage and administration (275) 275
urology & nephrology (265) 265
follow-up studies (264) 264
calcium channel blockers - therapeutic use (263) 263
combination (263) 263
amiloride - therapeutic use (260) 260
antihypertensive drugs (259) 259
urine (257) 257
captopril (249) 249
enalapril (249) 249
management (248) 248
tetrazoles - administration & dosage (247) 247
potassium (244) 244
amlodipine - therapeutic use (243) 243
captopril - therapeutic use (240) 240
mortality (240) 240
furosemide - pharmacology (239) 239
medicine & public health (239) 239
angiotensin ii type 1 receptor blockers - therapeutic use (233) 233
prevention (233) 233
telmisartan (231) 231
enalapril - therapeutic use (221) 221
methods (219) 219
atenolol (218) 218
pharmacokinetics (217) 217
performance liquid-chromatography (216) 216
hydrochlorothiazide - analysis (214) 214
pharmacology (212) 212
drug interactions (211) 211
tetrazoles - adverse effects (211) 211
valine - analogs & derivatives (210) 210
human plasma (209) 209
kidney - drug effects (207) 207
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8164) 8164
German (439) 439
Italian (285) 285
Russian (280) 280
French (190) 190
Spanish (144) 144
Japanese (64) 64
Chinese (57) 57
Polish (55) 55
Portuguese (50) 50
Czech (38) 38
Hungarian (19) 19
Danish (14) 14
Swedish (14) 14
Norwegian (13) 13
Croatian (12) 12
Romanian (12) 12
Dutch (11) 11
Korean (11) 11
Slovak (6) 6
Hebrew (5) 5
Turkish (5) 5
Bulgarian (3) 3
Finnish (3) 3
Ukrainian (3) 3
Lithuanian (2) 2
Persian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Water Research, ISSN 0043-1354, 01/2011, Volume 45, Issue 3, pp. 1432 - 1442
The occurrence of fifty-five pharmaceuticals, hormones and metabolites in raw waters used for drinking water production and their removal through a drinking... 
Drinking water | Chlorination | Ozonation | GAC | Hormones | Tap water | Pharmaceuticals | PERSONAL CARE PRODUCTS | POLAR DRUG RESIDUES | AQUATIC ENVIRONMENT | WATER RESOURCES | SURFACE-WATER | TANDEM MASS-SPECTROMETRY | ENVIRONMENTAL SCIENCES | ENGINEERING, ENVIRONMENTAL | WASTE-WATER | ENDOCRINE DISRUPTING COMPOUNDS | ORGANIC-COMPOUNDS | MULTI-RESIDUE ANALYSIS | NATIONAL RECONNAISSANCE | Pharmaceutical Preparations - isolation & purification | Sotalol - isolation & purification | Sotalol - chemistry | Phenytoin - isolation & purification | Carbamazepine - chemistry | Phenytoin - chemistry | Water Pollutants, Chemical - isolation & purification | Hormones - analysis | Atenolol - analysis | Carbamazepine - analogs & derivatives | Carbamazepine - analysis | Hormones - isolation & purification | Ozone - chemistry | Hydrochlorothiazide - chemistry | Water Pollutants, Chemical - chemistry | Hormones - chemistry | Water Pollutants, Chemical - analysis | Sotalol - analysis | Atenolol - chemistry | Pharmaceutical Preparations - chemistry | Hydrochlorothiazide - isolation & purification | Phenytoin - analysis | Atenolol - isolation & purification | Hydrochlorothiazide - analysis | Carbamazepine - isolation & purification | Pharmaceutical Preparations - analysis | Water Purification - methods | Water Supply - analysis | Ozonization | Metabolites | Atenolol | Phenytoin | Carbamazepine | Drugs | Filtration | Sand | Raw | Intakes
Journal Article
Journal of the Renin-Angiotensin-Aldosterone System, ISSN 1470-3203, 12/2015, Volume 16, Issue 4, pp. 1078 - 1084
Objective: We analyzed the efficacy and safety of combination therapy of high-dose losartan (100 mg/day) and hydrochlorothiazide (HCTZ, 12.5 mg/day) compared... 
Angiotensin II type 1 receptor blocker | Blood pressure | Hydrochlorothiazide | Uric acid | Losartan | CARDIOVASCULAR EVENTS | RISK | IDENTIFICATION | angiotensin II type 1 receptor blocker | BLOOD-PRESSURE | SERUM URIC-ACID | TELMISARTAN | TELMISARTAN/HYDROCHLOROTHIAZIDE | INHIBITION | hydrochlorothiazide | DISEASE | LOSARTAN/HYDROCHLOROTHIAZIDE | PERIPHERAL VASCULAR DISEASE | losartan | uric acid | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Antihypertensive Agents - administration & dosage | Systole - drug effects | Hypertension - drug therapy | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Dose-Response Relationship, Drug | Hypertension - blood | Uric Acid - urine | Heart Rate - drug effects | Hydrochlorothiazide - pharmacology | Female | Blood Pressure - drug effects | Diastole - drug effects | Uric Acid - blood | Drug Therapy, Combination | Hypertension - urine | Hydrochlorothiazide - adverse effects | Losartan - pharmacology | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - therapeutic use | Creatinine - urine | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Losartan - therapeutic use | Losartan - adverse effects | Potassium - blood | Aged | Losartan - administration & dosage | Hydrochlorothiazide - therapeutic use
Journal Article
Journal of Hypertension, ISSN 0263-6352, 05/2003, Volume 21, Issue 5, pp. 875 - 886
BACKGROUNDThe prognostic benefits of blood pressure lowering treatment in elderly hypertensive patients were established more than a decade ago, but are less... 
Hypertension | Cardiovascular events | Angiotensin II type 1-receptor blockade | Cognitive function | Candesartan | Elderly | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Antihypertensive Agents - administration & dosage | Dementia - diagnosis | Dementia - physiopathology | Hypertension - drug therapy | Male | Dose-Response Relationship, Drug | Benzimidazoles - administration & dosage | Time Factors | Tetrazoles - administration & dosage | Aged, 80 and over | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Hypertension - mortality | Benzimidazoles - adverse effects | Hypertension - diagnosis | Benzimidazoles - therapeutic use | Cardiovascular Diseases - diagnosis | Hydrochlorothiazide - adverse effects | Severity of Illness Index | Cardiovascular Diseases - physiopathology | Double-Blind Method | Risk Reduction Behavior | Europe - epidemiology | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Biomarkers - blood | Antihypertensive Agents - therapeutic use | Cognition - drug effects | Antihypertensive Agents - adverse effects | Survival Analysis | Helsinki Declaration | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Hydrochlorothiazide - therapeutic use | Comparative Study | Cardiovascular Diseases/diagnosis/mortality/physiopathology | Dose-Response Relationship; Drug | Biological Markers/blood | Europe/epidemiology | Aged; 80 and over | Research Support; Non-U.S. Gov't | Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Hydrochlorothiazide/administration & dosage/adverse effects/therapeutic use | Tetrazoles/administration & dosage/adverse effects/therapeutic use | Dementia/diagnosis/physiopathology | Blood Pressure/drug effects | Cognition/drug effects | Hypertension/diagnosis/drug therapy/mortality
Journal Article
Journal Article
Journal Article
Drugs, ISSN 0012-6667, 6/2009, Volume 69, Issue 9, pp. 1239 - 1265
Losartan/hydrochlorothiazide (HCTZ) [Hyzaar®] is a fixed-dose combination of the angiotensin II receptor antagonist (angiotensin receptor blocker [ARB])... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | II RECEPTOR ANTAGONIST | pharmacodynamics | ANTIHYPERTENSIVE EFFICACY | CARDIOVASCULAR MORBIDITY | Losartan/hydrochlorothiazide | ANGIOTENSIN-CONVERTING ENZYME | END-POINT REDUCTION | left ventricular hypertrophy | tolerability | pharmacokinetics | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | FIXED-DOSE COMBINATION | LOSARTAN PLUS HYDROCHLOROTHIAZIDE | TOXICOLOGY | hypertension | therapeutic use | HIGH BLOOD-PRESSURE | ACTIVE METABOLITE | Hydrochlorothiazide - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - adverse effects | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - economics | Tissue Distribution | Drug Interactions | Hypertrophy, Left Ventricular - drug therapy | Losartan - pharmacokinetics | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Antihypertensive Agents - economics | Hydrochlorothiazide - adverse effects | Losartan - economics | Stroke - prevention & control | Risk Reduction Behavior | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - therapeutic use | Hydrochlorothiazide - economics | Antihypertensive Agents - adverse effects | Animals | Losartan - therapeutic use | Hypertension - complications | Losartan - adverse effects | Diuretics - therapeutic use | Losartan - administration & dosage | Hydrochlorothiazide - therapeutic use | Drug Combinations | Hypertension | Heart enlargement | Losartan | Dosage and administration | Drug therapy, Combination | Hydrochlorothiazide | Diagnosis | Research | Drug therapy | Health aspects | Risk factors | Index Medicus
Journal Article
Journal Article
INTERNATIONAL JOURNAL OF PHARMACEUTICS, ISSN 0378-5173, 04/2017, Volume 521, Issue 1-2, pp. 73 - 83
An innovative pediatric oral formulation of hydrochlorothiazide (HCT) (2 mg/mL), endowed with improved bioavailability and sustained release properties and... 
VITRO | Pediatrics | Oral bioavailability | DIURETIC ACTIVITY | NLC | STABILITY | COMPLEXES | CONTROLLED DRUG-DELIVERY | Hydrochlorothiazide | CARRIERS | Cyclodextrin | SLN | PHYSICOCHEMICAL CHARACTERIZATION | BETA-CYCLODEXTRIN | Sustained release | PHARMACOLOGY & PHARMACY | Solid lipid nanoparticles | Hydrochlorothiazide - pharmacokinetics | Nanoparticles - chemistry | Antihypertensive Agents - administration & dosage | Drug Carriers - administration & dosage | Biological Availability | Delayed-Action Preparations - chemistry | Hypertension - drug therapy | Lipids | Male | Drug Carriers - chemistry | Delayed-Action Preparations - administration & dosage | Nanoparticles - metabolism | Cyclodextrins - chemistry | Drug Compounding | Poloxamer - administration & dosage | Poloxamer - chemistry | Drug Evaluation, Preclinical - methods | Administration, Oral | Poloxamer - pharmacokinetics | Cyclodextrins - pharmacokinetics | Hydrochlorothiazide - chemistry | Rats | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - pharmacokinetics | Rats, Sprague-Dawley | Hypertension - metabolism | Antihypertensive Agents - chemistry | Animals | Cyclodextrins - administration & dosage | Pediatrics - methods | Nanoparticles - administration & dosage | Hypertension | Product enhancement | Analysis | Diuretics | Cyclodextrins | Dextrins | Nanoparticles | Surface active agents | Drug therapy, Combination | Children | Health aspects | Index Medicus
Journal Article